Overview

Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Akershus
Collaborator:
Solvay Pharmaceuticals
Treatments:
Levodopa